ChiCTR2100046843 版本V1.0 版本创建时间2021/12/23 20:19:17 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100046843 

最近更新日期:

Date of Last Refreshed on:

2021-05-29 02:04:32 

注册时间:

Date of Registration:

2021-05-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

多模态磁共振指导发病时间不明确急性卒中患者血管内治疗和预后评估

Public title:

Multimodal magnetic resonance guided intravascular treatment and prognosis evaluation in acute stroke patients with uncertain onset time

注册题目简写:

English Acronym:

研究课题的正式科学名称:

多模态磁共振指导发病时间不明确急性卒中患者血管内治疗和预后评估

Scientific title:

Multimodal magnetic resonance guided intravascular treatment and prognosis evaluation in acute stroke patients with uncertain onset time

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈飞 

研究负责人:

陈飞 

Applicant:

Chen Fei 

Study leader:

Chen Fei 

申请注册联系人电话:

Applicant telephone:

15151070182

研究负责人电话:

Study leader's
telephone:

15151070182

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ycsycf@njmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

ycsycf@njmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省盐城市新都西路2号

研究负责人通讯地址:

江苏省盐城市新都西路2号

Applicant address:

No.2 Xindu West Road, Yancheng City, Jiangsu Province, China

Study leader's address:

No.2 Xindu West Road, Yancheng City, Jiangsu Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

盐城市第三人民医院

Applicant's institution:

Yancheng Third People's Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019094

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

盐城市第三人民医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Yancheng Third People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2019-12-06 00:00:00

伦理委员会联系人:

张亚军

Contact Name of the ethic committee:

Zhang Yajun

伦理委员会联系地址:

江苏省盐城市新都西路2号

Contact Address of the ethic committee:

No.2 Xindu West Road, Yancheng City, Jiangsu Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

盐城市第三人民医院

Primary sponsor:

Yancheng Third People's Hospital

研究实施负责(组长)单位地址:

江苏省盐城市新都西路2号

Primary sponsor's address:

No.2 Xindu West Road, Yancheng City, Jiangsu Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

盐城

Country:

China

Province:

Jiangsu

City:

Yancheng

单位(医院):

盐城市第三人民医院

具体地址:

新都西路2号

Institution
hospital:

Yancheng Third People's Hospital

Address:

2 Xindu Road West

经费或物资来源:

江苏省卫生健康委员会

Source(s) of funding:

Jiangsu Commission of Health

研究疾病:

急性脑卒中  

Target disease:

Acute cerebral stroke

研究疾病代码:

Target disease code:

研究类型:

预后研究

Study type:

Prognosis study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例研究 

Study design:

Case study 

研究目的:

联合多b值DWI的IVIM模型参数和3D-pcASL的CBF参数进行多参数分析,并结合FLAIR序列和MRA,指导发病时间不明的急性脑梗死血管内治疗并进行预后评估。  

Objectives of Study:

Combined with the IVIM model parameters of multi-B-value DWI and CBF parameters of 3D-PCASL, multi-parameter analysis was performed, combined with FLAIR sequence and MRA, to guide the intravascular treatment and prognosis assessment of acute cerebral infarction with unknown onset time.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

⑴急性脑梗死诊断标准符合《中国急性缺血性脑卒中诊治指南2018》;⑵患者确诊为发病时间不明的急性脑梗死;⑶MR检查之前无相关治疗;⑷无MR检查禁忌症,检查过程配合良好;⑸由2位医师共同观察患者各序列各层面图像均无运动伪影。

Inclusion criteria

(1) The diagnostic criteria for acute cerebral infarction conform to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018;(2) The patient was diagnosed with acute cerebral infarction of unknown onset time.⑶ There was no relevant treatment before MR examination;(4) No contraindications for MR examination, good coordination in the examination process;(5) There was no motion artifact in each sequence and layer image of the patient observed by 2 physicians.

排除标准:

⑴合并脑出血、肿瘤、血管畸形等其他神经系统疾病;⑵MR检查前接受过相关治疗;⑶图像具有运动伪影;⑷未获得患者知情同意书。

Exclusion criteria:

(1) Complicated with cerebral hemorrhage, tumor, vascular malformation and other neurological diseases;⑵ received relevant treatment before MR examination;(3) The image has motion artifacts;(4) No informed consent was obtained.

研究实施时间:

Study execute time:

From 2021-05-01 00:00:00 To 2024-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-06-01 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

血管内治疗组

样本量:

80

Group:

Group with intravascular treatment

Sample size:

干预措施:

血管内取栓

干预措施代码:

Intervention:

Intravascular thrombectomy

Intervention code:

组别:

常规治疗组

样本量:

80

Group:

Group with conventional treatment

Sample size:

干预措施:

药物治疗

干预措施代码:

Intervention:

Drug treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

盐城 

Country:

China

Province:

Jiangsu

City:

Yancheng

单位(医院):

盐城市第三人民医院 

单位级别:

三级甲等 

Institution
hospital:

Yancheng Third People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

美国国立卫生院神经功能缺损

指标类型:

主要指标

Outcome:

National Institutes of Health neurological deficits

Type:

Primary indicator

测量时间点:

入院,2周,3月

测量方法:

神经内科医师评估

Measure time point of outcome:

Admission, Two weeks, Three weeks

Measure method:

Evaluation by neurologist

指标中文名:

改良Rankin量表

指标类型:

主要指标

Outcome:

the Modified Rankin scale

Type:

Primary indicator

测量时间点:

入院,2周,3月

测量方法:

神经内科医师评估

Measure time point of outcome:

Admission, Two weeks, Three weeks

Measure method:

Evaluation by neurologist

指标中文名:

多b值DWI的IVIM模型参数

指标类型:

主要指标

Outcome:

Intravoxel incoherent motion model parameters of multi-B value diffusion weighted imaging

Type:

Primary indicator

测量时间点:

入院,2周,3月

测量方法:

磁共振成像

Measure time point of outcome:

Admission, Two weeks, Three weeks

Measure method:

Magnetic resonance imaging

指标中文名:

三维伪连续动脉自选标记

指标类型:

主要指标

Outcome:

3D pseudo continuous arterial spin labeling (3D-pcASL)

Type:

Primary indicator

测量时间点:

入院,2周,3月

测量方法:

磁共振成像

Measure time point of outcome:

Admission, Two weeks, Three weeks

Measure method:

Magnetic resonance imaging

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Not random

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024年10月前,通过百度网盘公开,https://pan.baidu.com/disk/home?_at_=1622007971285#/all?path=%2F&vmode=list

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

By October 2024, it will be made public through Baidu's online disk, https://pan.baidu.com/disk/home?_at_=1622007971285#/all?path=%2F&vmode=list

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

包含病例记录表和原始数据,存入网盘,在试验完成后6个月内公开

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The case record sheet and original data were stored on the network disk and made public within 6 months after the completion of the trial.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-05-29 02:04:32